These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11366230)

  • 21. Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain.
    Xiong YZ; Chen FE; Balzarini J; De Clercq E; Pannecouque C
    Chem Biodivers; 2009 Apr; 6(4):561-8. PubMed ID: 19353537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
    Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
    J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model.
    Xu ZQ; Hollingshead MG; Borgel S; Elder C; Khilevich A; Flavin MT
    Bioorg Med Chem Lett; 1999 Jan; 9(2):133-8. PubMed ID: 10021914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1.
    Wu B; Kuhen K; Ngoc Nguyen T; Ellis D; Anaclerio B; He X; Yang K; Karanewsky D; Yin H; Wolff K; Bieza K; Caldwell J; He Y
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3430-3. PubMed ID: 16632349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 27. In vitro selection of mutations in human immunodeficiency virus type 1 reverse transcriptase that confer resistance to capravirine, a novel nonnucleoside reverse transcriptase inhibitor.
    Sato A; Hammond J; Alexander TN; Graham JP; Binford S; Sugita K; Sugimoto H; Fujiwara T; Patick AK
    Antiviral Res; 2006 Jun; 70(2):66-74. PubMed ID: 16472877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug watch.
    Whitson S
    Posit Aware; 1999; 10(3):16-7. PubMed ID: 11366758
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural compound shows anti-HIV activity.
    AIDS Patient Care STDS; 1998 May; 12(5):410. PubMed ID: 11361986
    [No Abstract]   [Full Text] [Related]  

  • 31. University of Washignton AIDS Clinical Trials Unit.
    STEP Perspect; 1999; 99(3):21. PubMed ID: 11366867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HIV-1 activities in extracts from some medicinal plants as assessed in an in vitro biochemical HIV-1 reverse transcriptase assay.
    Kanyara JN; Njagi EN
    Phytother Res; 2005 Apr; 19(4):287-90. PubMed ID: 16041768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DPC-083. DuPont Pharmaceuticals.
    Lim ML
    Curr Opin Investig Drugs; 2001 Sep; 2(9):1209-12. PubMed ID: 11717806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calanolide looks promising.
    AIDS Patient Care STDS; 2000 Apr; 14(4):225-6. PubMed ID: 10806645
    [No Abstract]   [Full Text] [Related]  

  • 37. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
    Selmi B; Deval J; Boretto J; Canard B
    Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus.
    Wang Q; Ding ZH; Liu JK; Zheng YT
    Antiviral Res; 2004 Dec; 64(3):189-94. PubMed ID: 15550272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experts discuss findings on drug resistance.
    Mellors J; Kemp S
    AIDS Alert; 2001 Aug; 16(8):103-4. PubMed ID: 11547700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.